​

Nuvectis Pharma Stock (NASDAQ:NVCT)

OwnershipFinancialsChart
Nuvectis Pharma by TradingView

Previous Close

$6.38

52W Range

$4.44 - $12.10

50D Avg

$5.41

200D Avg

$6.45

Market Cap

$123.07M

Avg Vol (3M)

$164.82K

Beta

0.40

Div Yield

-

NVCT Company Profile

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 04, 2022

Website

NVCT Performance

NVCT Financial Summary

Dec 23Dec 22Dec 21
Revenue-$149.00K-
Operating Income$-45.79M$-19.23M$-12.89M
Net Income$-22.26M$-18.79M$-12.89M
EBITDA$-45.79M$-19.23M$-12.89M
Basic EPS$-1.43$-1.48$-1.01
Diluted EPS$-1.43$-1.48$-1.01

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
GOSSGossamer Bio, Inc.
CCCCC4 Therapeutics, Inc.
CMPXCompass Therapeutics, Inc.
KRONKronos Bio, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
LYRALyra Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.
CELCCelcuity Inc.
NAMSNewAmsterdam Pharma Company N.V.
GLUEMonte Rosa Therapeutics, Inc.
OLMAOlema Pharmaceuticals, Inc.
OBIOOrchestra BioMed Holdings, Inc.
IVAInventiva S.A.
LRMRLarimar Therapeutics, Inc.
REPLReplimune Group, Inc.
EWTXEdgewise Therapeutics, Inc.
CNTACentessa Pharmaceuticals plc
CGEMCullinan Oncology, Inc.
AVTEAerovate Therapeutics, Inc.
IKNAIkena Oncology, Inc.